Voyager Therapeutics' Seasoned Management And Leading Adeno-Associated Virus Capsid Platform Impress Bullish Analyst

Truist Securities analyst Joon Lee initiated coverage on Voyager Therapeutics Inc VYGR with a Buy rating at a price target of $18.
The analyst believes VYGR is a leader in CNS-targeted AAV capsids, developing gene therapies for diseases such as ALS, Alzheimer's, Parkinson's and Huntington's.
Lee thinks the company's existing partnerships, which offered non-dilutive financing of over $450 million to date, have the potential for up to $5 billion in additional milestones.
The analyst is also bullish on a solid management team, with the new CEO, Dr Al Sandrock, capable of helping VYGR cruise through scientific, regulatory and commercial hurdles. Also, the recent appointment of Dr George Scangos to VYGR's Board of Directors makes the analyst optimistic.
Lee sees the filing of VYGR's first IND using novel capsids in H1 2024 as a growth catalyst.
The analyst expects EPS of $1.11 in 2023 vs. consensus of $(1.94) and $(3.00) in 2024 compared to the consensus of $(1.97).
Yesterday, the company reported a Q1 2023 revenue of $150.5 million, surpassing the consensus of $41.0 million, while EPS of $2.94 exceeded the consensus of $0.77.
Price Action: VYGR shares are trading lower by 10.22% at $9.66 on the last check Wednesday.

Earnings Calendar